Impact of timing of adjuvant radiotherapy on locoregional control in patients with high-risk endometrial cancer

Abstract

Aim: High-risk endometrial cancer has a higher risk of regional and distant recurrence. We sought to examine our institutional experience regarding the timing of adjuvant radiotherapy and local failure (LF), locoregional failure (LRF), distant failure (DF), and overall survival (OS).

Methods: We retrospectively reviewed a database of patients with high-risk endometrial cancer treated with sequential chemotherapy followed by adjuvant external beam radiation therapy (EBRT) with or without brachytherapy from 2012 to 2019.

Results: One hundred thirty-one patients were identified. The median age at diagnosis was 65 (range 32-81). The most prevalent FIGO stages were IIIB (28.2%, n = 37), IIIC1 (19.8%, n = 26), and IIIA (17.6%, n = 23). Of the patients, 29% (n = 38) had positive lymph nodes and 71% (n = 93) had negative lymph nodes. The most prevalent histology was endometrioid (71%, n = 93), serous (12.2%, n = 16), clear cell (9.2%, n = 12), and other (7.6%, n = 10). Moreover, 100% (n = 131) of the patients completed EBRT. The mean EBRT dose was 49.6 Gy (range 45-50.4). The median number of days between surgery and EBRT was 212.4 days (range 103-219). The mean brachytherapy dose was 14.7 Gy (range 12-30). The cumulative incidence of LF was 6.1%, LRF was 19%, DF was 19%, and the median survival was 33.4 months. For patients who completed EBRT 180 days after surgery, LRF (HR 3.55 [1.23-10.2], P = 0.013), LF (HR 1.91 [0.4-8.9], P = 0.429), DF (HR 0.91 [0.41-2], P = 0.806), and OS (HR 0.92 [0.33-2.6], P = 0.87).

Conclusion: In our cohort of patients with high-risk endometrial cancer treated with chemotherapy followed by radiotherapy, delaying RT was associated with an increased risk of LRF but no differences in DF or OS.

Keywords

Locally advanced endometrial cancer / high-risk endometrial cancer / adjuvant radiotherapy / adjuvant chemotherapy / timing of radiotherapy

References

[1] Koskas M,Mirza MR.Cancer of the corpus uteri: 2021 update.Int J Gynaecol Obstet2021;155 Suppl 1:45-60 PMCID:PMC9297903

[2] Bhatla N,Sharma DN.Cancer of the cervix uteri: 2021 update.Int J Gynaecol Obstet2021;155 Suppl 1:28-44 PMCID:PMC9298213

[3] Concin N,Vergote I.ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.Int J Gynecol Cancer2021;31:12-39

[4] Murali R,Fadare O.High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations.Int J Gynecol Pathol2019;38 Suppl 1:S40-63 PMCID:PMC6296248

[5] Brooks RA,Lastra RR.Current recommendations and recent progress in endometrial cancer.CA Cancer J Clin2019;69:258-79

[6] Bendifallah S,Daraï E.High risk endometrial cancer: clues towards a revision of the therapeutic paradigm.J Gynecol Obstet Hum Reprod2019;48:863-71

[7] Randall ME,McMeekin DS.Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer.J Clin Oncol2019;37:1810-8

[8] Nout RA,Putter H.Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.Lancet2010;375:816-23

[9] Homesley HD,Gibbons SK.A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a gynecologic oncology group study.Gynecol Oncol2009;112:543-52 PMCID:PMC4459781

[10] Barton MB,Shafiq J.Role of radiotherapy in cancer control in low-income and middle-income countries.Lancet Oncol2006;7:584-95

[11] Greven K,Underhill K,Cooper J.Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.Int J Radiat Oncol Biol Phys2004;59:168-73

[12] Hogberg T,de Oliveira CF.Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.Eur J Cancer2010;46:2422-31 PMCID:PMC3552301

[13] Matei D,Randall ME.Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer.N Engl J Med2019;380:2317-26 PMCID:PMC6948006

[14] Tung HJ,Lai CH.Adjuvant and post-surgical treatment in endometrial cancer.Best Pract Res Clin Obstet Gynaecol2022;78:52-63

[15] Luo L,Zhigang Z,Alektiar K.Association of delayed adjuvant therapy and overall survival in early stage endometrial cancer.J Clin Oncol2017;99:E301

[16] Coleman MP,Bryant H.Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.Lancet2011;377:127-38 PMCID:PMC3018568

[17] Johnson N,Bailey D.Delays in treating endometrial cancer in the South West of England.Br J Cancer2011;104:1836-9 PMCID:PMC3111203

[18] Cattaneo R 2nd,Jacobsen G.Interval between hysterectomy and start of radiation treatment is predictive of recurrence in patients with endometrial carcinoma.Int J Radiat Oncol Biol Phys2014;88:866-71

[19] Neron M,Thezenas S.Impact of time to radiation therapy in adjuvant settings in endometrial carcinoma: a multicentric retrospective study.Eur J Obstet Gynecol Reprod Biol2020;247:121-6

[20] Dolly D,Rimel BJ.A delay from diagnosis to treatment is associated with a decreased overall survival for patients with endometrial cancer.Front Oncol2016;6:31 PMCID:PMC4751250

[21] de Boer SM,Mileshkin L.Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.Lancet Oncol2019;20:1273-85

[22] Lu SM,Hwang-Graziano J.Sequential versus “sandwich” sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.Gynecol Oncol2015;137:28-33

[23] Onal C,Yildirim BA.A multi-institutional analysis of sequential versus “sandwich” adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma.J Gynecol Oncol2019;30:e28 PMCID:PMC6424855